Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review
Dalbavancin (DAL) is a lipoglycopeptide with bactericidal activity against a very wide range of Gram-positive microorganisms. It also has unique pharmacokinetic properties, namely a prolonged half-life (around 181 h), which allows a convenient weekly dosing regimen, and good diffusion in bone tissue...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6382/10/6/656 |
| _version_ | 1797531915824136192 |
|---|---|
| author | Luis Buzón-Martín Ines Zollner-Schwetz Selma Tobudic Emilia Cercenado Jaime Lora-Tamayo |
| author_facet | Luis Buzón-Martín Ines Zollner-Schwetz Selma Tobudic Emilia Cercenado Jaime Lora-Tamayo |
| author_sort | Luis Buzón-Martín |
| collection | DOAJ |
| description | Dalbavancin (DAL) is a lipoglycopeptide with bactericidal activity against a very wide range of Gram-positive microorganisms. It also has unique pharmacokinetic properties, namely a prolonged half-life (around 181 h), which allows a convenient weekly dosing regimen, and good diffusion in bone tissue. These features have led to off-label use of dalbavancin in the setting of bone and joint infection, including prosthetic joint infections (PJI). In this narrative review, we go over the pharmacokinetic and pharmacodynamic characteristics of DAL, along with published in vitro and in vivo experimental models evaluating its activity against biofilm-embedded bacteria. We also examine published experience of osteoarticular infection with special attention to DAL and PJI. |
| first_indexed | 2024-03-10T10:51:35Z |
| format | Article |
| id | doaj.art-5a4523c40b374b158eaa8412d84f37df |
| institution | Directory Open Access Journal |
| issn | 2079-6382 |
| language | English |
| last_indexed | 2024-03-10T10:51:35Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj.art-5a4523c40b374b158eaa8412d84f37df2023-11-21T22:10:17ZengMDPI AGAntibiotics2079-63822021-05-0110665610.3390/antibiotics10060656Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative ReviewLuis Buzón-Martín0Ines Zollner-Schwetz1Selma Tobudic2Emilia Cercenado3Jaime Lora-Tamayo4Department of Internal Medicine, Infectious Diseases Division, Hospital Universitario de Burgos, 09006 Burgos, SpainSection of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Medical University of Graz, 8036 Graz, AustriaDepartment of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, 1090 Wien, AustriaServicio de Microbiología y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, 28007 Madrid, SpainBone and Joint Infection Study Group of the Spanish Society of Infectious Diseases and Clinical Microbiology (GEIO-SEIMC), 28003 Madrid, SpainDalbavancin (DAL) is a lipoglycopeptide with bactericidal activity against a very wide range of Gram-positive microorganisms. It also has unique pharmacokinetic properties, namely a prolonged half-life (around 181 h), which allows a convenient weekly dosing regimen, and good diffusion in bone tissue. These features have led to off-label use of dalbavancin in the setting of bone and joint infection, including prosthetic joint infections (PJI). In this narrative review, we go over the pharmacokinetic and pharmacodynamic characteristics of DAL, along with published in vitro and in vivo experimental models evaluating its activity against biofilm-embedded bacteria. We also examine published experience of osteoarticular infection with special attention to DAL and PJI.https://www.mdpi.com/2079-6382/10/6/656dalbavancinprosthetic joint infectiongram-positive |
| spellingShingle | Luis Buzón-Martín Ines Zollner-Schwetz Selma Tobudic Emilia Cercenado Jaime Lora-Tamayo Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review Antibiotics dalbavancin prosthetic joint infection gram-positive |
| title | Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review |
| title_full | Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review |
| title_fullStr | Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review |
| title_full_unstemmed | Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review |
| title_short | Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review |
| title_sort | dalbavancin for the treatment of prosthetic joint infections a narrative review |
| topic | dalbavancin prosthetic joint infection gram-positive |
| url | https://www.mdpi.com/2079-6382/10/6/656 |
| work_keys_str_mv | AT luisbuzonmartin dalbavancinforthetreatmentofprostheticjointinfectionsanarrativereview AT ineszollnerschwetz dalbavancinforthetreatmentofprostheticjointinfectionsanarrativereview AT selmatobudic dalbavancinforthetreatmentofprostheticjointinfectionsanarrativereview AT emiliacercenado dalbavancinforthetreatmentofprostheticjointinfectionsanarrativereview AT jaimeloratamayo dalbavancinforthetreatmentofprostheticjointinfectionsanarrativereview |